Rice ML, Wong B, Horn PS, Yang MB. Cataract development
associated with long-term glucocorticoid therapy in Duchenne muscular
dystrophy patients. J AAPOS. 2018 May 4. pii: S1091-8531(17)30954-0. doi:
10.1016/j.jaapos.2018.01.017.[Epub ahead of print]
Abstract
PURPOSE:
To evaluate the development of cataracts or ocular
hypertension in patients with Duchenne muscular dystrophy (DMD) on long-term GC
treatment.
METHODS:
The medical records of DMD patients evaluated from 2010 to
2015 at a single center were reviewed retrospectively. The main outcome
measures were prevalence of cataracts and ocular hypertension, age of first
detection of cataract, time from initial steroid use to first detection of
cataract, and relative risk of cataract development for deflazacort versus
prednisone treatment.
RESULTS:
Of 596 DMD patients, 514 underwent GC therapy; all but one
was male. The racial distribution was 82.1% white, 1.0% African American, 5.0%
Hispanic, 2.9% Asian, and 8.0% more than one race or "other." The
prevalence of cataracts was 22.4% in patients on GC therapy. The mean age at
which cataract formation was first documented was 12.9 ± 4.1 years (IQR,
9.6-14.6). The mean time from initial steroid use to the first detection of
cataract was 6.5 ± 3.6 years (IQR, 4.0-8.6). The odds of cataract development
were 2.4-fold higher for patients on deflazacort compared with prednisone (95%
CI, 1.3-4.5; P = 0.004). Only 7 patients (1.4%) underwent cataract surgery, at
a mean age of 16.9 years (range, 10.7-24.6 years); all were on deflazacort.
Among patients with available intraocular pressure measurements, ocular
hypertension occurred in only 1 patient (1.1%), who was on deflazacort.
CONCLUSIONS:
In patients undergoing GC therapy for DMD, the rate of
cataract formation was slow and well tolerated, with a higher risk among
deflazacort patients. The percentage of patients requiring cataract extraction
or with ocular hypertension was very small. These findings suggest that a
schedule of annual eye examinations is appropriate.
Courtesy of: https://www.mdlinx.com/neurology/medical-news-article/2018/05/08/ocular-hypertension-duchenne-muscular-dystrophy-glucocorticoid/7512922
No comments:
Post a Comment